Kenai Therapeutics Announces $82 Million Series A Financing to Advance Next Generation Allogeneic Cell Therapies for Neurological Diseases

SAN DIEGO–(BUSINESS WIRE)–Kenai Therapeutics Announces $82 Million Series A Financing to Advance Next Generation Allogeneic Cell Therapies for Neurological Diseases
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks